Kelyniam Global Announces Q2 2025 Financial Results
Kelyniam Global Announces Q2 2025 Financial Results |
[11-August-2025] |
CANTON, Conn., Aug. 11, 2025 /PRNewswire/ -- Kelyniam Global, Inc. (OTC: KLYG), a leading manufacturer of custom cranial and craniofacial implants, today announced its financial results for the half year ending on June 30, 2025. "The Company made up significant ground from the difficult comparisons in the first quarter," said Ross Bjella, CEO of Kelyniam. "Kelyniam focused its efforts on sales execution and the 2nd quarter on quarter results improved nicely over Q1 performance. The cranial implant market is driven by unforeseeable events and some time periods are busier than others. Q1 this year was just a slower period and our distributors worked hard to capture as many available opportunities as possible in Q2." Q2 2025 Financial Highlights (compared to Q2 2024):
Desiree Webb, Kelyniam's Chief Operating and Revenue Officer said, "Kelyniam's unique advantage of delivering complex custom cranial and craniofacial implants within 24-48 hours for rush and expedited cases allows us to pivot quickly for surgeons, sales reps and distributors. The Company experienced greater sales over the prior year in the latter part of Q2 in part to a laser focus on sales as we head into the trauma season." The Company held its annual shareholder meeting on June 23rd and all matters of official business passed with record levels of participation. Kelyniam's complete financial results are available at www.kelyniam.com. About Kelyniam Global, Inc. Forward-Looking Statements
SOURCE Kelyniam Global Inc | ||
Company Codes: OTC-PINK:KLYG,OTCB: KLYG,OTC:KLYG,OTC-BB:KLYG |